Ventricular tachyarrhythmias represent a serious and time-sensitive complication of digoxin toxicity. Management in this scenario follows a defined pathway with a clear primary goal.
The patient presents with cardiac glycoside (digoxin) toxicity and has developed ventricular tachyarrhythmias. This specific arrhythmic presentation requires a targeted treatment approach.
The clinical target is resolution of ventricular tachyarrhythmias. When the preferred first-line treatment for this indication is not immediately available, specific antiarrhythmic agents are used as an alternative — the selection and sequencing of which are defined in the full protocol.
Complete agent selection, clinical decision points, and the full management algorithm are available in the structured protocol below.
DOI: 10.1097/MEJ.0000000000001065
If digoxin immune Fab is not immediately available, ventricular tachyarrhythmias can be treated with lidocaine or magnesium sulfate.
View source ↗